Nanobody-based CAR T cells targeting intracellular tumor antigens
Chimeric antigen receptor (CAR) T-cell immunotherapy has become one of the research hotspots in the treatment of malignant tumors nowadays. However, the available tumor surface antigens are limited in number. Most tumor-associated antigens are intracellular molecules that can’t be targeted by conven...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332222013087 |
| _version_ | 1811221050864697344 |
|---|---|
| author | Haixia Li Dani Zhong Huiguan Luo Wei Shi Shenxia Xie Hangbiao Qiang Lichen Zhu Li Gao Jun Liu Shuyang Sun Ziqiang Ding Xiaomei Yang Xiaoling Lu |
| author_facet | Haixia Li Dani Zhong Huiguan Luo Wei Shi Shenxia Xie Hangbiao Qiang Lichen Zhu Li Gao Jun Liu Shuyang Sun Ziqiang Ding Xiaomei Yang Xiaoling Lu |
| author_sort | Haixia Li |
| collection | DOAJ |
| description | Chimeric antigen receptor (CAR) T-cell immunotherapy has become one of the research hotspots in the treatment of malignant tumors nowadays. However, the available tumor surface antigens are limited in number. Most tumor-associated antigens are intracellular molecules that can’t be targeted by conventional CAR T cells. As the major histocompatibility complex (MHC)/peptide complex is a presentation form of intracellular proteins on the surface of tumor cells, here, we chose the Glypican-3 (GPC3) oncoprotein and Wilms tumor 1 (WT1) oncoprotein as examples to explore whether nanobody (Nb)-based T cell receptor (TCR)-like CAR T cells could kill tumor cells by targeting the MHC/peptide complexes. Using the immune nanobody phage display library, we developed human leukocyte antigen (HLA)-A2/GPC3- and HLA-A2/WT1-specific nanobodies for the first time and then incorporated these nanobodies in two TCR-like CARs, targeting HLA-A2/GPC3 and HLA-A2/WT1 respectively. These TCR-like Nb CAR-redirected T cells could selectively recognize and lyse MHC/peptide complex-expressing tumor cells in vitro assays and subcutaneous mouse tumor models. This study offers a possible strategy for targeting intracellular antigens and widening the application of CAR T-cell therapy. |
| first_indexed | 2024-04-12T07:52:59Z |
| format | Article |
| id | doaj.art-231c0e07cf034f2599f12622f02125a2 |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-04-12T07:52:59Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-231c0e07cf034f2599f12622f02125a22022-12-22T03:41:33ZengElsevierBiomedicine & Pharmacotherapy0753-33222022-12-01156113919Nanobody-based CAR T cells targeting intracellular tumor antigensHaixia Li0Dani Zhong1Huiguan Luo2Wei Shi3Shenxia Xie4Hangbiao Qiang5Lichen Zhu6Li Gao7Jun Liu8Shuyang Sun9Ziqiang Ding10Xiaomei Yang11Xiaoling Lu12Guangxi Key Laboratory of Nanobody Research, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; Guangxi Nanobody Engineering Research Center, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; School of Basic Medical Sciences, Guangxi Medical University, Nanning, ChinaGuangxi Key Laboratory of Nanobody Research, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; Guangxi Nanobody Engineering Research Center, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting tumor Diagnosis and Therapy, Guangxi Talent Highland of Bio-targeting Theranostics, Guangxi Medical University, Nanning, China; Oncology Medical College, Guangxi Medical University, Nanning, ChinaGuangxi Key Laboratory of Nanobody Research, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; Guangxi Nanobody Engineering Research Center, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; The Second Clinical Medical College, Guangxi Medical University, Nanning, ChinaGuangxi Key Laboratory of Nanobody Research, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; Guangxi Nanobody Engineering Research Center, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; Laboratory Animal Center, Guangxi Medical University, Nanning, ChinaGuangxi Key Laboratory of Nanobody Research, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; Guangxi Nanobody Engineering Research Center, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; Pharmaceutical College, Guangxi Medical University, Nanning, ChinaGuangxi Key Laboratory of Nanobody Research, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; Guangxi Nanobody Engineering Research Center, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; School of Basic Medical Sciences, Guangxi Medical University, Nanning, ChinaGuangxi Key Laboratory of Nanobody Research, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; Guangxi Nanobody Engineering Research Center, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, ChinaGuangxi Key Laboratory of Nanobody Research, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; Guangxi Nanobody Engineering Research Center, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; School of Basic Medical Sciences, Guangxi Medical University, Nanning, ChinaGuangxi Key Laboratory of Nanobody Research, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; Guangxi Nanobody Engineering Research Center, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, ChinaGuangxi Key Laboratory of Nanobody Research, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; Guangxi Nanobody Engineering Research Center, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, ChinaGuangxi Key Laboratory of Nanobody Research, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; Guangxi Nanobody Engineering Research Center, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; School of Basic Medical Sciences, Guangxi Medical University, Nanning, ChinaGuangxi Key Laboratory of Nanobody Research, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; Guangxi Nanobody Engineering Research Center, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; School of Basic Medical Sciences, Guangxi Medical University, Nanning, China; Correspondence to: Guangxi Medical University, Nanning, Guangxi, China.Guangxi Key Laboratory of Nanobody Research, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; Guangxi Nanobody Engineering Research Center, College of Stomatology, Hospital of Stomatology, Guangxi Medical University, Nanning, China; Correspondence to: Guangxi Medical University, Nanning, Guangxi, China.Chimeric antigen receptor (CAR) T-cell immunotherapy has become one of the research hotspots in the treatment of malignant tumors nowadays. However, the available tumor surface antigens are limited in number. Most tumor-associated antigens are intracellular molecules that can’t be targeted by conventional CAR T cells. As the major histocompatibility complex (MHC)/peptide complex is a presentation form of intracellular proteins on the surface of tumor cells, here, we chose the Glypican-3 (GPC3) oncoprotein and Wilms tumor 1 (WT1) oncoprotein as examples to explore whether nanobody (Nb)-based T cell receptor (TCR)-like CAR T cells could kill tumor cells by targeting the MHC/peptide complexes. Using the immune nanobody phage display library, we developed human leukocyte antigen (HLA)-A2/GPC3- and HLA-A2/WT1-specific nanobodies for the first time and then incorporated these nanobodies in two TCR-like CARs, targeting HLA-A2/GPC3 and HLA-A2/WT1 respectively. These TCR-like Nb CAR-redirected T cells could selectively recognize and lyse MHC/peptide complex-expressing tumor cells in vitro assays and subcutaneous mouse tumor models. This study offers a possible strategy for targeting intracellular antigens and widening the application of CAR T-cell therapy.http://www.sciencedirect.com/science/article/pii/S0753332222013087CAR T-cell therapyNanobodyTCR-like antibodyIntracellular tumor antigen |
| spellingShingle | Haixia Li Dani Zhong Huiguan Luo Wei Shi Shenxia Xie Hangbiao Qiang Lichen Zhu Li Gao Jun Liu Shuyang Sun Ziqiang Ding Xiaomei Yang Xiaoling Lu Nanobody-based CAR T cells targeting intracellular tumor antigens Biomedicine & Pharmacotherapy CAR T-cell therapy Nanobody TCR-like antibody Intracellular tumor antigen |
| title | Nanobody-based CAR T cells targeting intracellular tumor antigens |
| title_full | Nanobody-based CAR T cells targeting intracellular tumor antigens |
| title_fullStr | Nanobody-based CAR T cells targeting intracellular tumor antigens |
| title_full_unstemmed | Nanobody-based CAR T cells targeting intracellular tumor antigens |
| title_short | Nanobody-based CAR T cells targeting intracellular tumor antigens |
| title_sort | nanobody based car t cells targeting intracellular tumor antigens |
| topic | CAR T-cell therapy Nanobody TCR-like antibody Intracellular tumor antigen |
| url | http://www.sciencedirect.com/science/article/pii/S0753332222013087 |
| work_keys_str_mv | AT haixiali nanobodybasedcartcellstargetingintracellulartumorantigens AT danizhong nanobodybasedcartcellstargetingintracellulartumorantigens AT huiguanluo nanobodybasedcartcellstargetingintracellulartumorantigens AT weishi nanobodybasedcartcellstargetingintracellulartumorantigens AT shenxiaxie nanobodybasedcartcellstargetingintracellulartumorantigens AT hangbiaoqiang nanobodybasedcartcellstargetingintracellulartumorantigens AT lichenzhu nanobodybasedcartcellstargetingintracellulartumorantigens AT ligao nanobodybasedcartcellstargetingintracellulartumorantigens AT junliu nanobodybasedcartcellstargetingintracellulartumorantigens AT shuyangsun nanobodybasedcartcellstargetingintracellulartumorantigens AT ziqiangding nanobodybasedcartcellstargetingintracellulartumorantigens AT xiaomeiyang nanobodybasedcartcellstargetingintracellulartumorantigens AT xiaolinglu nanobodybasedcartcellstargetingintracellulartumorantigens |